# 瑞士藥廠Novartis (NOVN.S)已與Argo Biopharmaceutical簽署高達52億美元的授權及選擇權協議，涵蓋其實驗性心血管藥物。

*biotech · news · 2025-09-03 · Reuters*

## Key points

- Novartis已與Argo Biopharmaceutical簽署價值高達52億美元的授權及選擇權協議。
- 該協議涵蓋包括一款處於中期臨床試驗的高血脂實驗性心血管藥物。
- Novartis已取得這些藥物在中國以外地區的銷售權利。
- Novartis已表達非約束性意向，參與Argo下一輪股權融資。

The company's logo is seen at a building of Swiss drugmaker Novartis in Rotkreuz, Switzerland, January 29, 2020. REUTERS/Arnd Wiegmann/ File Photo Purchase Licensing Rights , opens new tab Sept 3 (Reuters) - Swiss drugmaker Novartis (NOVN.S) , opens new tab has signed an up to $5.2 billion licensing and options deal with Argo Biopharmaceutical for its experimental cardiovascular drugs, the China-based biotech said on Wednesday. The deal includes an experimental genetic medicine in mid-stage study to control high blood fat levels and an option to license two drug candidates for high levels of certain blood cholesterols, which increase the risk of heart disease. Sign up here. The deals are for sales outside China, Argo said. The biotech, which develops genetic medicines, said Novartis has also expressed a non-binding intention to participate in its next round of equity financing. Reporting by Mariam Sunny in Bengaluru; Editing by Shinjini Ganguli and Sriraj Kalluvila Our Standards: The Thomson Reuters Trust Principles. , opens new tab

**Companies:** Novartis, Argo Biopharmaceutical
**Countries:** Switzerland, China

[Read the full story on Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-signs-up-52-billion-heart-drugs-licensing-deal-with-chinas-argo-2025-09-03/)

---

Canonical: https://newsio.io/zh-TW/n/574b339c-fec0-4386-8305-a71b83828394/novartis-novn-sargo-biopharmaceutical52
Summarized by Newsio from Reuters. https://newsio.io/how-it-works